Anteris Technologies Global Corp. aims to raise $75 million in an IPO for aortic stenosis treatment development in a growing ...

which is anticipated to offer fresh insights for global implanters treating symptomatic severe aortic stenosis (SASS). The ...

A large new population study of men over 45 indicates insulin resistance may be an important risk factor for the development ...

A recent study has revealed a strong link between insulin resistance and an increased risk of aortic stenosis (AS), a ...

Insulin resistance can increase the risk of aortic stenosis -- a common heart valve disease, in men over the age of 45, finds ...

In the CONDUCT-TAVI study, the use of a self-expanding valve was not associated with an increased risk of pacemaker.

Insulin resistance associated with prediabetes appears to raise a person’s risk of a common and serious heart valve ...

Medtronic announced the launch of its ALERT study, which aims to address racial, ethnic, gender and geographic disparities in ...

Abbott has taken a step forward in the development of a new addition to its structural heart portfolio, completing the first ...

The SMART trial raised questions about balloon-expandable valves in small aortic annuli; these new data offer some answers.

Abbott (NYSE: ABT) today announced the first patient procedures with its investigational transcatheter aortic valve implantation (TAVI) balloon-expandable system for treating symptomatic severe aortic ...